Litigation

Government Employees Health Association, Inc. v. Jazz Pharmaceuticals PLC

dismissed

1:20-cv-03673

Auto-generating section 1 of 5: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: N.D. Ill.
Filed: 2020-06-23
Terminated: 2020-07-14

Patents at issue (1)

Plaintiffs (1)

π Government Employees Health Association, Inc.

Defendants (1)

Δ Jazz Pharmaceuticals PLC

Summary

Antitrust/payor action in N.D. Ill. against Jazz Pharmaceuticals; US 6,780,889 is named among the patents at issue. Terminated on 2020-07-14, consistent with the July 2020 voluntary dismissals of payor suits to pursue claims in the N.D. Cal. MDL.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 6780889-1-20-cv-03673 · edit in Admin

Further reading

Joint defense groups: economics, formation, and the privilege framework
An NPE sues twenty defendants on one patent. Solo, each faces $3-5M in defense costs. Pooled into a joint defense group, the per-defendant number drops to $200-500K. The economics only work if the privilege framework is set up correctly.
§ 285 attorney-fee shifting in practice
§ 285 isn't a guaranteed remedy. It's a high-effort, high-evidence tool that pays off occasionally and dramatically — turning a $3M defense expense into a $3M plaintiff bill.
The patent litigation lifecycle
Most patent cases never reach trial. A defendant who understands the lifecycle makes better decisions about when to fight, when to settle, and when to invest in IPR — instead of overspending on whatever phase they happen to be in.
Declaratory judgment actions: when to flip the table on a patent troll
The patent holder is the one with the patent. They're not always the one who gets to pick the courtroom.
Bilski v. Kappos (2010)
Machine-or-transformation isn't the only § 101 test, business-method patents survived as a category, and the specific Bilski hedging method was unpatentable. The trio of Bilski, Mayo, and Alice gave defendants the modern § 101 motion.

All resources →